Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

INTRODUCTION: In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In phase 3 CARE-MS I...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurol Ther
Main Authors: Bertolotto, Antonio, Arroyo, Rafael, Celius, Elisabeth G., Comi, Giancarlo, Havrdova, Eva Kubala, Honeycutt, William David, Hunter, Samuel F., Izquierdo, Guillermo, Kornek, Barbara, Miller, Tamara, Mitsikostas, Dimos D., Singer, Barry A., Ziemssen, Tjalf, Chung, Luke, Daizadeh, Nadia, Afsar, Salman, Hashemi, Lobat, Senior, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606412/
https://ncbi.nlm.nih.gov/pubmed/32410147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40120-020-00191-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados